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Management of children with HIV/AIDS is specially challenging. Age-related issues do not
allow for direct transposition of adult observations to this population. CXCR4 tropism has
been  associated with disease progression in adults. The geno2pheno web-base is a friendly
tool to predict viral tropism on envelope V3 sequences, generating a false positive rate for a
CXCR4 prediction. We  evaluated the association of HIV-1 tropism prediction with clinical and
laboratory outcome of 73 children with HIV/AIDS in São Paulo, Brazil. The CXCR4 tropism
was  strongly associated with a lower (nadir) CD4 documented during follow-up (p < 0.0001)
and  with disease severity (clinical event and/or CD4 below 200 cells/mm3) at the last observa-
tion,  using commonly applied clinical cutoffs, such as 10%FPRclonal (p = 0.001). When variables
obtained  during follow-up are included, both treatment adherence and viral tropism show
a  signiﬁcant association with disease severity. As for viremia suppression, 30% (22/73) were
undetectable  at the last observation, with only adherence strongly associated with sup-pression  after adjustment. The study brings further support to the notion that antiretroviral
treatment  adherence is pivotal to management of HIV disease, but suggests that tropism
de an
acute  infection occurs during the neonatal period, a time
13 Eprediction  may provi
Introduction
Management of children with HIV/AIDS is specially chal-
© 20lenging.  Although antiretroviral (ARV) treatment may  lead
to  viremia control and clinical beneﬁt comparable to adult
patients,  time for treatment initiation, therapy change
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strategies, along with other age-related issues, pose addi-
tional  challenges, adding to higher risk of ARV failure among
children.1 For children with vertically-acquired infection,
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND. 42 Matisse, 05466-040 Sao Paulo, SP, Brazil.
characterized by exceedingly high viremia levels that decline,
albeit  more  slowly than in adults, over the next two or more
years  to reach a set point. This set point tends to be higher
 de CC BY-NC-ND
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drug);  (ii) resistance (intermediate or high) to drugs of onlyb r a z j i n f e c t d i s .
n children, as compared to adults, and is consistent with
ore  rapid disease progression.2–4Although the goal to elimi-
ate  HIV maternal-to-child-transmission (MTCT) is a current
riority  for international agencies, about 400,000 children are
nfected annually, and pediatric AIDS remains a major public
ealth  issue in many  areas. Moreover, for patients who receive
dequate  care and treatment, life expectancy is extended into
dulthood.  A better understanding of the pathogenesis of chil-
ren with HIV/AIDS is instrumental, as the clinical evolution
n  this population might differ from patients that acquire HIV
ith  a mature immune system.
Over the years, various clinical and laboratory mark-
rs  of disease progression have been proposed for adults
nd  children, although the determinants for disease pro-
ression,  especially in children, are unclear. The CD4+
-lymphocyte count (CD4) and viral load (VL) are the pri-
ary  markers that have been used in different studies to
nitiate  and monitor antiretroviral therapy (ART) in clini-
al  practice.5–9 Additional parameters could improve clinical
ecision-making, especially those that can predict disease
rogression. Viral envelope characteristics have been asso-
iated  with HIV pathogenesis since the beginning of the
pidemic.10 To initiate cellular infection, HIV needs to use
he  CD4 receptor along with a chemokine coreceptor, mostly
CR5  or CXCR4. Based on the coreceptor usage, HIV-1 vari-
nts  may  be classiﬁed as R5-tropic, X4-tropic or dual-tropic
DM).  While most primary infections involve viruses that
se  CCR5 as a coreceptor, CXCR4-using viruses are often
dentiﬁed in adults with advanced disease and its identiﬁ-
ation  has been associated with rapid progression.11–14 Viral
ropism,  although a phenotypic characteristic, can be pre-
icted  with genotypic methods. These tests have greater
ccessibility, lower cost, and shorter assay time than pheno-
ypic  methods.15,16
The identiﬁcation of surrogate markers that provide clues
o  the clinical outcome may  be useful to subsidize clinical
ecision. The aim of this study was  to evaluate HIV tropism
enotypic prediction from the ﬁrst available clinical sam-
le  and its association with disease progression in a clinical
ohort  of children and adolescents with HIV/AIDS in São Paulo,
razil.
aterials  and  methods
tudy  population
he study was  offered to all parents or responsible guardians
f  children or adolescents in regular follow-up at the Pedi-
tric  Infectious Diseases Unit of Santa Casa Hospital, São
aulo,  from 2000 to 2010. Inclusion criteria consisted of being
ounger  than 19 years, not being pregnant and having written
nformed  consent signed by parents or guardians, with assent
rom  older children and adolescents. Clinical and laboratory
ata  were  obtained by Medical Record review. Since March
000,  blood samples from new patients initiating follow-up
ave  been sent to Adolfo Lutz Institute laboratory. Of the
7  children seem at this pediatric clinic, 73 had envelope
equence and VL information. Of those, 63 had also both
linical  and CD4 outcome information and for 58 of those4;1 8(3):300–307  301
three  or more  CD4 determinations (a median of eight CD4
determinations) allowed the deﬁnition of a lower (nadir) CD4
count.
The  study was  approved by the two institutions, Institute
Adolfo Lutz (CCD-BM 20/08) and Santa Casa Hospital (ISCMSP
015/10).
Disease  progression was  evaluated according to three crite-
ria:
(i)  CD4 count (nadir) during follow-up;
(ii) VL at last observation;
(iii)  a composite criteria combining CD4 and clinical disease
at  last observation:
•  Asymptomatic disease (AD): children clinically asymp-
tomatic with CD4 > 200 cells/mm3 or
•  Symptomatic disease (SD): children with either
CD4 < 200 cells/mm3, clinical event, deﬁned as Centers
for  Disease Control and Prevention (CDC) classiﬁcation
system clinical category B or C, or death.
Ampliﬁcation  and  sequencing
HIV viral RNA from plasma was  isolated using QIAamp®
viral RNA mini kit (Qiagen, Germany), according to manufac-
turer’s  instructions. Complementary DNA synthesis (cDNA)
was  performed using SuperScript III enzyme (Life Tech-
nologies, USA) and random hexamers. Cell DNA was
extracted using QIAamp® viral DNA mini kit (Qiagen, Ger-
many),  according to manufacturer’s instructions. A nested
PCR  allowed for the ampliﬁcation of the C2-V3 envelope
region using primers ED5, ED12, ED31 and ES8, applying
previously described protocols.17–19 Puriﬁed products were
sequenced in automated ABI 3100 or 3130 XL Genetic
Analyzers (Applied Biosystems, USA). All sequenced chro-
matograms obtained were assembled with Sequencher 4.14
(GeneCodes,  USA) software and manually edited, considering
nucleotide ambiguities whenever a signiﬁcant secondary peak
(∼25%) was  present in two or more  chromatograms. Edited
sequences were evaluated individually at websites (see below)
and  multiple alignments were performed using ClustalW
multiple-sequence alignment software, using a reference set
available in the Los Alamos HIV-1 database (www.hiv.lanl.gov)
and manually edited according to their reading frame, using
BioEdit  software.
HIV-1  clade was screened at NCBI Genotyping and REGA
HIV-1  Subtyping Tools and conﬁrmed by phylogenetic meth-
ods,  using PAUP software. Drug resistance mutations (DRM)
were  analyzed at Stanford HIV Database and resistance was
evaluated  by drug class (nucleoside reverse transcriptase
inhibitor [NRTI] DRM, non-nucleoside reverse transcriptase
inhibitor [NNRTI] DRM and protease inhibitor [PI] DRM), as
well  as combined resistance, such as: (i) no DRM  (including
polymorphisms without major loss of susceptibility to anyone  ARV class; (iii) resistance to drugs in two classes and; (iv)
resistance  to drugs in all three classical classes. Resistance to
new classes (integrase inhibitors and entry inhibitors) was  not
evaluated.
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Table 1 – Baseline demographic and laboratory data of
study  participants.
Age, years 7 (IQR 2–13)
Male gender (%) 42.5 (31/73)
HIV transmission (%)
Vertical  94.5 (69/73)
Unknown 5.5 (4/73)
CDC clinical category (%)
N  14 (10/73)
A 10 (7/73)
B 19 (14/73)
C 57 (42/73)
CD4 (cells/mm3) 442 (IQR 156–951)
Viral load (log10) 5.2 (IQR 4.4–5.7)
ARV naïve at ﬁrst visit (%) 55 (40/73)
Table 1 describes baseline demographic and laboratory data of
study participants; Age, at study entry, in years (median, 25th–75th
interquartile range – IQR); Gender as percentage of males; HIV
transmission mode, percentage of cases with documented verti-
cal transmission mode, unknown for cases without clear mode of
transmission; CDC classiﬁcation clinical categories (N, A, B, C) as
percentage of cases at study entry; CD4, CD4+ T lymphocytes count
(median, IQR of number of cells/mm3); Viral load (median, IQR of
HIV RNA copies/mL in log10); ARV naïve at ﬁrst visit, percentage of302  b r a z j i n f e c t d 
Determination  of  HIV-1  viral  tropism
Viral coreceptor tropism prediction, based on edited partial
envelope  sequences, was  evaluated at the G2P website consid-
ering  the clonal option to determine the false positive rate
(FPR).  The FPR is thus the probability (0–1) of a false CXCR4
assignment to a non-CXCR4 envelope sequence. These results
were  analyzed both as continuous and dichotomous (R5/X4)
variables,  using the three most widely used cutoffs (20%, 10%
and  5.75%) to categorize HIV-1 as only CCR5-tropic or CXCR4-
tropic.
Statistical  analyses
Tropism prediction was  evaluated with independent variables
of  demographic, clinical and laboratory data documented at
study entry, including sex, age at collection, clinical staging,
mode  of transmission, VL, CD4, CDC category, and previous
use  of ART and viral subtype at envelope. Variables obtained
during  follow-up included VL, CD4, clinical events including
death,  adherence to ART, number of ARV regimens, DRM, and
polymerase  subtype. Dependent variables at outcome were:
(i)  Clinical condition and CD4 at last observation,
dichotomized at 200 cells/mm3 (CDC immunological
category 3 versus category 1 or 2), allowing disease
severity categorization as SD or AD at last observation (all
children  above 5 years of age at this CD4 determination);
(ii) Last VL dichotomized as undetectable (aviremia)/
detectable (viremia) VL.
The lower CD4 documented during follow-up (nadir CD4)
was  also evaluated as a marker of disease progression for
patients  with at least three determinations during follow-up.
To  evaluate differences among proportions the Pearson
Qui-square or Fisher Exact tests were  used, as appropriate.
The Mann–Whitney test was  used to compare medians and
ANOVA,  for multiple comparisons. Correlation of quantitative
variables was  performed with the Spearman test (PrismaPad)
and  non-parametric receiver operating characteristic (ROC)
curve  with Stata 8.0. A logistic regression analysis included all
variables  with p < 0.20 at univariate analysis. We  analyzed the
data  using two multiple models for each outcome. The ﬁrst
was  only based on the variables available at baseline (study
entry),  and the other considered all variables obtained during
follow-up,  evaluated together with those available at baseline
that  had a p < 0.20. Logistic regression analysis was  performed
using  the Stata 8.0 statistical software, applying a level of sig-
niﬁcance  of p < 0.05.
Results
Participant  characteristics
This longitudinal study included consenting 73 children
with  conﬁrmed HIV-1 infection and one or more envelope
sequences.
In  this analysis the ﬁrst available envelope sequence,
obtained during follow-up, was  used. The median age waspatients entering the study before ARV initiation.
seven years (ranging from two months to 18 years old) and
58%  of the patients were female. HIV-1 was acquired by ver-
tical  transmission in 69 patients and in 4 cases the mode of
transmission was  not documented. At baseline, median VL
was  5.2 log10 (IQR, 4.4–5.7 log10) and CD4 was  442 cells/mm3
(IQR, 156–951 cells/mm3), with a nadir of 149 cells/mm3 (IQR,
27–395  cells/mm3) during follow-up, with a median CD4  count
of  491 cells/mm3 (IQR, 271–954 cells/mm3) at the last observa-
tion  (Table 1). The patients were classiﬁed, according to CDC
classiﬁcation system clinical category, as N (14%), A (10%), B
(19%)  or C (57%). As for immunologic category, 28.7% were in
category  1, 32.9% in category 2 and 35.6% in category 3, with
two  cases with missing data.
Most patients 40/73 (55%) were ARV naïve at collection
for envelope sequencing, but all eventually initiated ART in
a  short period thereafter (median 19 days, [IQR, 10–71 days]).
ART  initiation depended on drug availability at the time of
initiation,  and mono-dual therapy was used by 46% of the
patients  as the ﬁrst regimen. Part of the patients (n = 33) ini-
tiated  treatment before inclusion, some at other services.
The  median time on treatment was 7.8 years (IQR, 2.2–10.7
years).  Among those starting with highly active antiretrovi-
ral  therapy (HAART), the most common combination was a
NNRTI (efavirenz [EFV] or nevirapine [NVP]) combined with
zidovudine  (ZDV) and lamivudine (3TC), used by 31% of the
patients.  At last documented treatment, most cases were  on
a  lopinavir/ritonavir (LPV/r) based HAART (45%). Patients used
a  median of three regimens (IQR, 1–5 regimens) during follow-
up.
Patients  were followed in the study for a median time of
6.1  years (IQR, 1.5–11.6 years). During follow-up, 59% (34/58)
of  the patients had at least one documented undetectable VL
(viremia  < 50 copies/mL) at some time during ART and 30%
b r a z j i n f e c t d i s . 2 0 1 4;1 8(3):300–307  303
Table 2a – Association of clinical and laboratory data with the last viral load (viremic or aviremic).
Variable OR (95% IC) p-Value aOR (95% IC) p-Value
Age 1.16 (1.04–1.29) 0.006 1.2 (1.1–1.37) 0.008
Sex 1.91 (0.67–5.46) 0.23
Clinical at entry 0.63 (0.21–1.89) 0.41
Naïve at collection 0.99 (0.36–2.69) 0.98
First viremia 0.71 (0.45–1.13) 0.15 1.02 (0.56–1.9) 0.904
First CD4 0.70 (0.37–1.30) 0.26
Env subtype 1.42 (0.44–4.54) 0.56
Tropism 20% 2.23 (0.78–6.38) 0.14
Tropism 10% 2.90 (0.86–9.84) 0.09 5 (1.3–19) 0.03
Tropism 5.75% 2.89 (0.75–11.21) 0.12
OR, Unadjusted Odds Ratio; aOR, Adjusted Odds Ratio; CI, Conﬁdence Interval; Outcome: last viral load observation as viremic or aviremic (below
50 copies/mL). Age, at study entry; sex for patient gender; clinical at entry as asymptomatic (CDC clinical categories N or A) or symptomatic (CDC
B or C); naïve at collection for patients entering the study before ARV initiation; ﬁrst viremia and ﬁrst CD4 for viral load and CD4+ T-lymphocyte
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higher  nadir CD4 predicted a good clinical and CD4  outcome
(p  = 0.001).
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22/73) were  undetectable at last observation. The viremic
ases  had a median VL of 4.20 log10 (IQR, 3.7–5 log10).
Adherence was  documented in 63 cases, 26 (41%) of whom
ad  good adherence, deﬁned by the physician’s perception
ased  on reports of missing zero to only a few pills in recent
RV  regimens.
Genotype test was  obtained in 68 cases, with 58% of those
ith  one or more  NRTI mutations, 51% with a NNRTI muta-
ion  and 35% with one or more  major PI mutations. One class
esistance  was  documented in 17% of the cases, two-class
esistance in 21% and three-class resistance in 24%.
enotypic  tropism  testing  and  subtyping
ropism prediction was  obtained in 73 cases. Using the
0%FPRclonal cutoff, 55% (40/73) were  classiﬁed as R5 tropism,
7% (49/73) at 10%FPRclonal and 74% using 5.75%FPRclonal cutoff.
here was  a signiﬁcant correlation of a lower FPRclonal with
ncreasing age (p = 0.02).
Subtype B at envelope region was  documented in 53 (72.6%)
ases,  HIV-1 F in 16 (22%), subtype C in three (4%), with one BF
ecombinant. At polymerase (n = 68) 74% of sequences were
IV-1  subtype B, 11% F, 4.5% C and 10.5% BF recombinants. In
5% (10/68), there was  polymerase/envelope subtype discord-
nce  (B/F or F/B recombinants).
HIV-1  subtype C, all concordant in polymerase/envelope,
ere all classiﬁed as R5 HIV-1 infection, with a good clinical
nd  CD4 outcome. For further analysis we  categorized sub-
ypes  as HIV-1 B and non-B.
ropism  association  with  HIV  disease  progression
verall, seven deaths occurred in this cohort. Three patients
ied  after progressing to AIDS in the ﬁrst year of life, with
omplications associated with the diagnosis of Pneumocys-
is  jiroveci pneumonia (2) and intestinal cytomegalovirus. All
10%hree would be classiﬁed as R5 using the FPRclonal and 2/3,
f  the 20%FPRclonal was  used. Older children dying from AIDS-
elated conditions tended to have very low FPRclonal (3/4 X4,
ith  a FPRclonal below 0.02).ignment for the envelope region; tropism 20%, 10%, and 5.75% for
Tables  2a and 2b describe the variables associated with
aviremia (VL < 50 copies/mL) in this cohort. Being older at the
ﬁrst  observation was associated with virologic suppression.
The  R5 tropism showed no signiﬁcant association (p = 0.09). All
variables with p < 0.2 were included in multivariate analysis;
older  age at blood collection and R5 tropism showed a signiﬁ-
cant  association. However, when all variables obtained during
follow-up  were evaluated in multivariate analysis, adherence
showed  the strongest association with viral suppression, with
older  age marginally associated with suppression.
The association of viral tropism with CD4 was  more notice-
able.  The nadir CD4 showed a strong positive correlation
with the FPRclonal (p = 0.0011, Fig. 1) values and R5-predicted
envelope sequences had a signiﬁcantly higher nadir CD4 as
compared  to X4 in all clinical cutoffs: 5.75%FPRclonal (p = 0.0002),
10%FPRclonal (p = 0.0001) and at 20%FPRclonal (p < 0.0001). The area
under the curve of the ROC curve of nadir CD4  for viral tropism
using  the 10%FPRclonal cutoff is 0.82 (95% CI 0.68–0.95) (Fig. 2). AFig. 1 – Spearman correlation between the V3  sequences’
false  positive rate (FPR) and the lower CD4 count (nadir CD4)
observed  for cases with at least 3 CD4 measures (median of
8 measures; IQR, 4–12 measures).
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Table 2b – Association between aviremia (viral load < 50 copies/mL) and data from the last observation.
Variable OR (95% IC) p-Value aOR (95% IC) p-Value
DRM 0.81 (0.5–1.3) 0.401
NRTI DRM 0.79 (0.57–1.1) 0.182
NNRTI DRM 0.89 (0.53–1.5) 0.646
PI major DRM 0.59 (0.29–1.2) 0.140 0.32 (0.097–1.03) 0.057
Adherence 0.17 (0.06–0.53) 0.002 0.10 (0.01–0.57) 0.010
ARV regimens 0.88 (0.57–1.36) 0.57
Pol subtype 0.41 (0.13–1.34) 0.14 0.27 (0.1–1.5) 0.141
Nadir CD4 1.19 (0.75–1.89) 0.45
Tropism 10% 2.90 (0.86–9.84) 0.087 5.3 (0.7–42) 0.113
Age at collection 2.01 (1.21–3.32) 0.007 2.6 (1–6.6) 0.049
OR, Unadjusted Odds Ratio; aOR, Adjusted Odds Ratio; CI, Conﬁdence Interval; DRM for any drug resistance mutation that impact ARV suscep-
tibility (according to Stanford database); NRTI DRM for nucleoside reverse transcriptase inhibitor mutations; NNRTI DRM for non-nucleoside
reverse transcriptase inhibitor mutations; PI major DRM for major protease inhibitor resistance mutations; adherence as physicians perception
of patient adherence to antiretroviral therapy; pol subtype: HIV-1 subtype assigned for the polymerase region; ARV regimens for the number of
different ARV regimens used during observation.
Tables 2a and 2b show Odds Ratio (OR) and level of signiﬁcance (p) of univariate and multivariate logistic regression analysis. (2a) for variables
available upon entering follow-up and in 2b for variables obtained during follow-up along those available upon entering that had a p < 0.2.
iffere
djustmFor potential co-linear variables, such as tropism prediction using d
variables in the univariate analysis were carried on to multivariate a
Using the last CD4 determination alone, above or below
200  cells/mm3, we  observed that children with CD4 below
200  cells/mm3 had a signiﬁcantly lower FPRclonal, 0.035,
whereas cases with CD4 above 200 had 0.29 (p = 0.0026), with a
consequent higher proportion of X4 prediction. At 10%FPRclonal,
only  5/16 (31%) of R5 tropism prediction is observed for cases
with  CD4 below 200 cells/mm3, whereas those with CD4 above
200  cells/mm3 were  mostly R5 (79%, 44/56, p = 0.001).
We also evaluated the association of viral tropism to dis-
ease  severity (n = 63) dichotomizing cases in two categories:
(i)  AD outcome and (ii) SD outcome. In the univariate analy-
sis  (Tables 3a and 3b), we  observed that having a R5-predicted
tropism, by any of the clinical cutoffs, was  associated with
AD.  A higher CD4 (CDC category) was  also marginally protec-
tive.  When we  analyze with other variables obtained during
follow-up,  better adherence, lower number of regimens and
aviremia  showed association with AD outcome. R5 tropism
0.00
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Area under ROC curve = 0.8160
Fig. 2 – Receiver operating characteristic curve of nadir CD4
using  as reference variable the HIV-1 viral tropism predicted
at  the 10%FPRclonal cutoff, showing an area under the curve
(AUC)  of 0.816; the use of other FPR cutoffs (5.75% and 20%)
show  a similar AUC (0.824 and 0.819, respectively).nt cutoffs, or antiretroviral resistance by class, the most signiﬁcant
ent.
and adherence remained signiﬁcantly associated with protec-
tion  at multivariate analysis.
Some  samples for tropism determination were available
only  near the time of the last observation. The median follow-
up  time after sample collection used in tropism prediction was
1.2  years (IQR, 6 days to 5.4 years). This period was similar
between disease severity (p = 0.7) or aviremia (p = 0.9) outcome
categories. However, if only children with more  than one year
of  observation after envelope analysis were included (n = 40),
still  a signiﬁcantly lower FPR (median 0.035 IQR 0.015–0.215)
is  observed among those with severe clinical progression,
whereas those with AD disease had a higher FPR (0.37, IQR
0.16–0.47,  p = 0.0015). Using the 10%FPRclonal, 10/16 with X4 pre-
dicted tropism had severe disease as compared to 3/24 with R5
predicted virus (p = 0.003). The difference for viremia outcome
was  not signiﬁcant (p = 0.6).
Discussion
The main purpose of this study was  to document clinical and
laboratory  evolution of this cohort to evaluate if tropism deter-
mination  can be useful as a marker of disease progression.
For this purpose, a longitudinal follow-up of HIV-1-infected
children and adolescents was  carried out for over 10 years,
documenting known predictors of disease progression, such
as  CD4 counts and adherence to treatment. One major limi-
tation  of the study is the fact that tropism determination was
not  performed at study entry, but sometime during follow-
up,  with some cases determined at the sample available near
last  observation. Therefore, the study can only suggest poten-
tial  associations, and cannot claim that the predicted tropism
determined the outcome evaluated. Also, as in other longi-
tudinal  studies in clinical settings, different factors, such as
assiduity  of patients, parents or guardians, proper collection
and  storage of the samples, documentation of clinical and
laboratory  data throughout the follow-up impact data collec-
tion,  and missing data compromise a robust support to our
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Table 3a – Association of information available at study entry with clinical severity.
Variable OR (95% IC) p-Value aOR (95% IC) p-Value
Age at collection 1.09 (0.69–1.7) 0.71
Sex 0.96 (0.34–2.8) 0.95
Clinic stage at entry 2.16 (0.66–7.03) 0.201 0.83 (0.20–3.5) 0.80
Naïve at collection 2.29 (0.79–6.61) 0.125 2.2 (0.59–8.39) 0.52
Viremia 1.06 (0.66–1.69) 0.81
CD4 0.53 (0.26–1.04) 0.07 0.47 (0.20–1.1) 0.078
Env subtype 0.82 (0.26–2.60) 0.74
Tropism 20% 5.33 (1.74–16.28) 0.003
Tropism 10% 7.37 (2.03–22.7) 0.001 6.34 (1.58–22.6) 0.008
Tropism 5.75% 6.42  (1.85–22.3) 0.003
OR, Unadjusted Odds Ratio; aOR, Adjusted Odds Ratio; CI, Conﬁdence Interval; Clinical Severity outcome means children with either
CD4 < 200 cells/mm3, clinical event, deﬁned as Centers for Disease Control and Prevention (CDC) classiﬁcation system clinical category B or
C, or death. Age, at study entry; sex for patient gender; clinical at entry as asymptomatic (CDC clinical categories N or A) or symptomatic (CDC
B or C); naïve at collection for patients entering the study before ARV initiation; ﬁrst viremia and ﬁrst CD4 for viral load and CD4+ T-lymphocyte
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prediction using three cutoffs at geno2pheno.
ndings. Although clinical trials provide a stronger basis for
he  development of cohort studies, the ability to grasp real
orld  dynamics makes clinical setting observations also rele-
ant.
Brazil  has the largest pediatric population with HIV/AIDS
ith  public access to both monitoring tools, as well as ART.
ittle  work, however, is available on the long-term evaluation
f  these patients, some already initiating follow-up in adult
ervices.
Patients  in this study were  followed up at a single clini-
al  site in São Paulo, the largest city in South America. The
ervice  studied is not a speciﬁc reference center for AIDS or for
nfected pregnant women  and therefore receives sick children
hat  end up ﬁnding their HIV diagnosis during the evalua-
ion  at entry. Most children observed without ART at entry
ere  brought to the service due to some clinical condition
Table 3b – Association of follow-up information and signiﬁcant
Variable OR (95% IC) p
First CD4 category 0.53 (0.27–1.04) 0
ARV Regimens 0.81 (0.66–098) 0
DRM 0.80 (0.49–1.32) 0
NRTI DRM 0.79 (0.60–1.05) 0
NNRTI DRM 0.86 (0.51–1.41) 0
PI major DRM 0.63 (0.38–1.03) 0
Polsubtype 0.59 (0.16–2.19) 0
Adherence 0.091 (0.02–0.45) 0
Everavir 0.31 (0.10–0.95) 0
Aviremia 10.5 (2.17–50.1) 0
Tropism 10% 7.4 (2.23–22.4) 0
OR, Unadjusted Odds Ratio; aOR, Adjusted Odds Ratio; CI, Conﬁdence Inte
tibility (according to Stanford database); NRTI DRM for nucleoside reverse
reverse transcriptase inhibitor mutations; PI major DRM for major protease
of patient adherence to antiretroviral therapy; pol subtype: HIV-1 subtype 
different ARV regimens used during observation; Everavir for one or more
viremia at last observation.
Tables  3a and 3b show Odds Ratio (OR), 95% conﬁdence interval (CI95%)
regression analyses. In 3a, associations with disease severity of variables
follow-up among those available at entry that had a p < 0.2. For potential 
ARV resistance by class, the most signiﬁcant variable in the univariate ananment for the envelope region; tropism 20%, 10%, 5.75% for tropism
and initiated ARV shortly after this initial observation. This
might  have caused an inclusion bias toward more  severe cases.
Another  issue is the fact that the service cares for patients
without insurance and therefore includes a signiﬁcant pro-
portion  of children from lower income strata. However, the
population  of the study had some degree of homogeneity,
such as access to free ARV, socio cultural background and the
fact  that all were treated by the same clinical team, diminish-
ing  the variability in clinical management. Because of limited
numbers  of infected children and of mothers with relevant
data,  we  were  unable to investigate effects of other factors pos-
sibly associated with disease progression in vertically infected
children,  such as maternal ART use and maternal VL.
Children in clinical services are followed based on clinical
condition, routine laboratory workup, and two major HIV-
related  prognostic markers, CD4 and VL. Although clinical
 entry observations with clinical severity.
-Value aOR (95% IC) p-Value
.066 0.86 (0.27–2.9) 0.299
.034 0.51 (0.29–1.26) 0.147
.386
.117
.544
.067 0.69 (0.22–1.79) 0.537
.428
.003 0.04 (0.02–0.79) 0.032
.040
.003 1.3 (0.5–11) 0.816
.001 10.3 (1.5–72) 0.019
rval; DRM for any drug resistance mutation that impact ARV suscep-
 transcriptase inhibitor mutations; NNRTI DRM for non-nucleoside
 inhibitor resistance mutations; adherence for physicians perception
assigned for the polymerase region; ARV regimens for the number of
 undetectable viral load during follow up; Aviremia for undetectable
 and level of signiﬁcance (p) of univariate and multivariate logistic
 available upon entering the study. 3b for variables obtained during
co-linear variables, as tropism prediction using different cutoffs, or
lysis were carried on to multivariable adjustment.
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evolution will be inﬂuenced by different biological, socio cul-
tural  and access to health-related issues, it is conceivable that
certain  viral characteristics may  inﬂuence this outcome. Viral
tropism  has been suggested to be an additional marker of dis-
ease  severity in adults.13
Although viral tropism is more  properly evaluated using
phenotypic assays, genotypic methods allow for a reasonable
prediction, and have been increasingly used. Moreover, it was
considered  sufﬁcient by the European Consensus Group to
deﬁne  tropism for the usage of CCR5 antagonists.14 In our
study,  we  did not try to evaluate the tropism assay itself, but
rather  correlate the genotypic prediction with the actual clin-
ical  and laboratory outcomes of these patients. To that end,
we  analyzed envelope sequences at the geno2pheno web-
site,  a commonly used resource that provides a FPR for the
probability  of misclassifying a sequence as X4. Therefore,
the  lower the FPR, the lower the chance of false X4 clas-
siﬁcations. As different clinical cutoffs have been used, we
evaluated  our dataset with the three most commonly used
cutoffs.
This  study showed a relatively high proportion of X4-
predicted variants, 45% if a more  conservative (20%FPRclonal)
cutoff  is used. Some previous studies reported similar preva-
lence  in chronically infected children.20,21 One study with
HIV-1  subtype C infected children, observed a lower presence
of  X4,22 similar to a study in Uganda with different subtypes,23
whereas others found a higher X4 prevalence.24 The differ-
ences  in study design, population, age of participants, tropism
deﬁnition  and viral subtype may  all contribute to these dis-
crepancies.  Clade C cases are considered to be preferentially
R5  isolates, and in the small subgroup of clade C infection in
our  study we  also found only R5-predicted variants.
There was  a signiﬁcant correlation between a lower FPR
and  older age in our population. Other studies20,25 also found
that  correlation and that tendency is in accordance with most
of  the evidence in adults that suggests the emergence of X4
variants  later, as the disease progresses.12,26 In adults, after a
mostly  R5 infection, about 50% of HIV infected patients evolve
to  X4 tropic variants later in disease.13
Suppression of viremia is the main goal of HAART. At
last  observation, only 30% (22/73) of the patients achieved
aviremia. This ﬁgure is not unusual for children initiating
therapy before the HAART era, as is the case of many  of
these  patients. Response rates are better for children initiat-
ing  HAART with new regimens (data not shown). From the data
available upon entering follow-up, being older and having a R5
virus was  associated with virologic suppression in multivari-
ate  analysis (Tables 2a and 2b). However, the association of R5
with viral suppression is weak and not sustained when vari-
ables  obtained during follow-up are included. When follow-up
information is considered, the association of aviremia with
age  becomes less striking and adherence is the only strong
predictor  of aviremia. It is well known that a good adher-
ence  to ART is the central determinant of viral suppression
and long-term disease-free survival. This is a difﬁcult goal,
particularly in very young children who rely on parents or care-
givers  to administer drugs and in adolescents, who are more
likely  than younger children either to report poor adherence
themselves or to have it reported by caregivers and/or health
professionals.27 1 4;1  8(3):300–307
The association of age with viremia suppression may  be
due  to an easier adaptation of older children to ARV and to
the  bimodal nature of HIV disease in children, as pointed out
by  Puthanakit et al.28 in their study of treatment initiation in
older  children. Therefore, children who do not present clinical
disease  early after birth might already represent a population
of  better clinical outcome. Similarly, early deaths in the ﬁrst
year  may  represent either more  aggressive disease or cases
that  reached the service at an advance stage, in which clinical
intervention was of limited impact.
We did not ﬁnd an association between DRM  and viral sup-
pression.  It was  not the objective of this paper to evaluate this
issue,  and resistance was considered here as one of the pos-
sible  variables observed during follow-up that should be used
in  adjusting the multivariate analysis. The resistance proﬁle
and  viral diversity of pol gene in this population have been
previously published.29,30 The lack of correlation of DRM with
clinical  severity or viremia is possibly due to the fact that DRM
is  generally absent in samples from patients with adequate
adherence, aviremic cases, as well as from viremic, poorly
controlled, low adherence patients, as only those submitted
to  sufﬁcient drug exposure would develop genetic mutations.
Nevertheless, the genotypic test was helpful in guiding salvage
therapy  in many  patients (data not shown).
Contrary to viral suppression, CD4 levels, as well as a
composite outcome combining both CD4 and clinical condi-
tion,  showed a strong and independent association with viral
tropism.  Entry CD4 (CDC category) showed a tendency in pre-
dicting  a less severe outcome (p = 0.08). However, viral tropism,
specially  using the 10%FPRclonal cutoff shows an independent,
strong association with AD (Tables 2a and 2b) when only
information available at the study entry is considered. When
follow-up  information is included, ARV adherence and R5 viral
tropism are both signiﬁcantly associated to AD. We also found
a  strong, signiﬁcant correlation between FPR and CD4 nadir
values  (Fig. 1). There is evidence that immunologic deteriora-
tion  in HIV-1–infected children precedes the viral phenotypic
switch from R5 to X4 variants31 and that the presence of X4
variants  is linked with faster progression to AIDS, a rapid fall
in  CD4 count26 and a lower CD4 nadir. This association of
viral  tropism with CD4, but not with viremia control, has been
observed  in some studies with adult patients,13 and we  and
others32,33 have found an association of a lower geno2pheno
FPR with CD4 depletion in adults.
Since some of our cases had insufﬁcient follow-up time
after  tropism determination it is not possible to exclude the
possibility  that the predicted tropism was  secondary to clini-
cal  deterioration. The use of tropism prediction information,
in  a clinical setting context, may  assist pediatricians in plan-
ning  a more  aggressive intervention in cases with more  severe
prognosis,  maximizing resources available for populations
with  increased risk of disease progression. Current Brazilian
treatment guidelines indicate treatment for children with clin-
ical disease, VL above 100,000 copies/mL or CD4  below 25%.
Although  the efforts in improving adherence are a cornerstone
of  treatment success, information on viral tropism, along with
other  prognostic markers, could be useful to support clinical
decision.
In  conclusion, our study documented for the ﬁrst time
a  strong predictive association, independent from other
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vailable markers, that a high FPR, predicting a CCR5 core-
eptor  usage, is protective in children and is related to a better
mmunological (CD4 level) and clinical outcome.
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